ArticleRheumatology (Oxford, England)2025
Arterial cardiovascular outcomes and venous thromboembolism in patients with primary Sjögren's syndrome: a Danish cohort study.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk of venous, arterial, and rare thrombotic events in adults with Sjögren's disease: a systematic review and meta-analysis.Reumatologia · 2026Review
- Sjogren's Disease and Elevated Cardiovascular Risk: Mechanisms and Treatment.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether atherosclerotic cardiovascular disease outcomes, venous thromboembolism, heart failure, and cardiovascular mortality are elevated in patients with primary Sjögren's syndrome (pSS) compared with a matched cohort from the general population.
methodsWe conducted a nationwide population-based cohort study including all patients with a pSS diagnosis from 1996 to 2017 in Denmark, matched with a comparison cohort on age, gender, and calendar year. The cumulative incidence of each outcome was computed using hospital contact diagnoses as the end point. We used Cox regression to calculate hazard ratios (HRs) for the endpoints, adjusted for potential confounding factors.
resultsThe study included 4697 pSS patients (median age 57 years, 87% women) and 46 970 persons in a comparison cohort followed for a median of 7.6 years (maximum 23 years). After confounder adjustment, pSS was associated with elevated rates of myocardial infarction (adjusted hazard ratio [aHR] 1.23; 95% confidence interval [CI] 1.01-1.50), ischaemic stroke (aHR 1.31; 95% CI 1.14-1.52) and haemorrhagic stroke (aHR 1.51; 95% CI 1.13-2.03), peripheral artery disease (aHR 1.44; 95% CI 1.13-1.83), and venous thromboembolism (aHR 1.57; 95% CI 1.33-1.85). Cardiovascular death (aHR 1.11; 95% CI 0.95-1.30) and heart failure (aHR 1.17; 95% CI 0.99-1.39) were slightly elevated in patients with pSS.
conclusionThis study provides firm evidence that pSS is associated with increased risk of all atherosclerotic cardiovascular outcomes and venous thromboembolism, and highlights the importance of managing cardiovascular risk factors in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.